Open the mobile version, with barcode scanning
Class III Ongoing

Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, N…

Why: Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Company
Cipla USA, Inc.
Warren, NJ, United States
Reported
Mar 11, 2026
Recall started
Feb 18, 2026
Where sold
U.S.A. Nationwide
Amount
271 cartons - Ex: 84 outer cartons x 4 inner cartons x 4 blisters x 7 capsules
Full product description
Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC 69097-031-74; Inner carton: 28 capsules (4 blisters of 7 capsules) NDC 69097-031-56; Foil blister: NDC 69097-031-17
Lots / codes affected
Lot #: 5GJ0220, 5GJ0221, 5GJ0222, Exp 04/30/2027

Class I: could cause serious harm or death. Class II: could cause temporary or treatable problems. Class III: unlikely to cause harm.